Adipose targets for obesity drug development

Bibliography

• NEEL JV: Diabetes mellitus: a ‘thrifty’ genotype rendered detrimental by ‘progress’? Am. J. Hum. Genet. (1962) 14:353-362.
   PubMed Web of Science ®Google Scholar
• HAUNER H: Orlistat. In: Pharmacotherapy of Obesity: Options and Alternatives, Hofbauer KG, Keller U, Boss O (Eds.), CRC Press, Boca Raton, FL (2004):219-243.
   Google Scholar
• RYAN DH: Sibutramine. In: Pharmacotherapy of Obesity: Options and Alternatives, Hofbauer KG, Keller U, Boss O (Eds.), CRC Press, Boca Raton, FL (2004):245-266.
   Google Scholar
• WELLEN KE, HOTAMISLIGIL GS: Obesity-induced inflammatory changes in adipose tissue. J. Clin. Invest. (2003) 112(12):1785-1788.
   PubMed Web of Science ®Google Scholar
• HANSEN BC, BODKIN NL, ORTMEYER HK: Calorie restriction in nonhuman primates: mechanisms of reduced morbidity and mortality. Toxicol. Sci. (1999) 52(2 Suppl.):56-60.
   PubMed Web of Science ®Google Scholar
• BLANC S, SCHOELLER D, KEMNITZ J et al.: Energy expenditure of rhesus monkeys subjected to 11 years of dietary restriction. J. Clin. Endocrinol. Metab. (2003) 88(1):16-23.
   PubMed Web of Science ®Google Scholar
• POEHLMAN ET: Reduced metabolic rate after caloric restriction-can we agree on how to normalize the data? J. Clin. Endocrinol. Metab. (2003) 88(1):14-15.
   PubMed Web of Science ®Google Scholar
• DULLOO AG: A role for suppressed skeletal muscle thermogenesis in pathways from weight fluctuations to the insulin resistance syndrome. Acta Physiol. Scand. (2005) 184(4):295-307.
   PubMedGoogle Scholar
• DULLOO AG, JACQUET J: An adipose-specific control of thermogenesis in body weight regulation. Int. J. Obes. Relat. Metab. Disord. (2001) 25(Suppl. 5):S22-S29.
   Google Scholar
• RAVUSSIN E, KOZAK L: Energy Homeostasis. In: Pharmacotherapy of Obesity: Options and Alternatives, Hofbauer KG, Keller U, Boss O (Eds.), CRC Press, Boca Raton, FL (2004):3-23.
   Google Scholar
• FAIN JN, MADAN AK, HILER ML, CHEEMA P, BAHOUTH SW: Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology (2004) 145(5):2273-2282.
   PubMed Web of Science ®Google Scholar
• HAUNER H: Secretory factors from human adipose tissue and their functional role. Proc. Nutr. Soc. (2005) 64(2):163-169.
   PubMed Web of Science ®Google Scholar
• SALTIEL AR: You are what you secrete. Nat. Med. (2001) 7(8):887-888.
   PubMed Web of Science ®Google Scholar
• RAJALA MW, SCHERER PE: Minireview: The adipocyte-at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology (2003) 144(9):3765-3773.
   PubMed Web of Science ®Google Scholar
• FARMER SR, AUWERX J: Adipose tissue: new therapeutic targets from molecular and genetic studies-IASO Stock Conference 2003 report. Obes. Rev. (2004) 5(4):189-196.
   PubMedGoogle Scholar
• LAU DC, DHILLON B, YAN H, SZMITKO PE, VERMA S: Adipokines: molecular links between obesity and atheroslcerosis. Am. J. Physiol. Heart Circ. Physiol. (2005) 288(5):H2031-H2041.
   PubMed Web of Science ®Google Scholar
• MOLLER DE, KAUFMAN KD: Metabolic syndrome: a clinical and molecular perspective. Ann. Rev. Med. (2005) 56:45-62.
   PubMed Web of Science ®Google Scholar
• YANG Q, GRAHAM TE, MODY N et al.: Serum retinol binding protein 4 contributes to insulin resistance in obesity and Type 2 diabetes. Nature (2005) 436(7049):356-362.
   PubMed Web of Science ®Google Scholar
• LAFONTAN M: Fat cells: afferent and efferent messages define new approaches to treat obesity. Ann. Rev. Pharmacol. Toxicol. (2005) 45:119-146.
   PubMed Web of Science ®Google Scholar
• CHEN HC, RAO M, SAJAN MP et al.: Role of adipocyte-derived factors in enhancing insulin signaling in skeletal muscle and white adipose tissue of mice lacking acyl-CoA:diacylglycerol acyltransferase 1. Diabetes (2004) 53(6):1445-1451.
   PubMed Web of Science ®Google Scholar
• RABILLOUD T, KIEFFER S, PROCACCIO V et al.: Two-dimensional electrophoresis of human placental mitochondria and protein identification by mass spectrometry: toward a human mitochondrial proteome. Electrophoresis (1998) 19(6):1006-1014.
   PubMed Web of Science ®Google Scholar
• GYGI SP, RIST B, GERBER SA, TURECEK F, GELB MH, AEBERSOLD R: Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat. Biotechnol. (1999) 17(10):994-999.
   PubMed Web of Science ®Google Scholar
• MANN M, PANDEY A: Use of mass spectrometry-derived data to annotate nucleotide and protein sequence databases. Trends Biochem. Sci. (2001) 26(1):54-61.
   PubMed Web of Science ®Google Scholar
• KRATCHMAROVA I, KALUME DE, BLAGOEV B et al.: A proteomic approach for identification of secreted proteins during the differentiation of 3T3-L1 preadipocytes to adipocytes. Mol. Cell. Proteomics (2002) 1(3):213-222.
   PubMed Web of Science ®Google Scholar
• GIMENO RE, KLAMAN LD: Adipose tissue as an active endocrine organ: recent advances. Curr. Opin. Pharmacol. (2005) 5(2):122-128.
   PubMed Web of Science ®Google Scholar
• ZHANG Y, PROENCA R, MAFFEI M, BARONE M, LEOPOLD L, FRIEDMAN JM: Positional cloning of the mouse obese gene and its human homologue. Nature (1994) 372(6505):425-432.
   PubMed Web of Science ®Google Scholar
• HALAAS JL, GAJIWALA KS, MAFFEI M et al.: Weight-reducing effects of the plasma protein encoded by the obese gene. Science (1995) 269(5223):543-546.
   PubMed Web of Science ®Google Scholar
• PELLEYMOUNTER MA, CULLEN MJ, BAKER MB et al.: Effects of the obese gene product on body weight regulation in ob/ob mice. Science (1995) 269(5223):540-543.
   PubMed Web of Science ®Google Scholar
• FRIEDMAN JM, HALAAS JL: Leptin and the regulation of body weight in mammals. Nature (1998) 395(6704):763-770.
   PubMed Web of Science ®Google Scholar
• FAROOQI IS, MATARESE G, LORD GM et al.: Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J. Clin. Invest. (2002) 110(8):1093-1103.
   PubMed Web of Science ®Google Scholar
• HEYMSFIELD SB, GREENBERG AS, FUJIOKA K et al.: Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. J. Am. Med. Assoc. (1999) 282(16):1568-1575.
   PubMed Web of Science ®Google Scholar
• HUKSHORN CJ, SARIS WH, WESTERTERP-PLANTENGA MS, FARID AR, SMITH FJ, CAMPFIELD LA: Weekly subcutaneous pegylated recombinant native human leptin (PEG-OB) administration in obese men. J. Clin. Endocrinol. Metab. (2000) 85(11):4003-4009.
   PubMed Web of Science ®Google Scholar
• KLEIN S, COPPACK SW, MOHAMED-ALI V, LANDT M: Adipose tissue leptin production and plasma leptin kinetics in humans. Diabetes (1996) 45(7):984-987.
   PubMed Web of Science ®Google Scholar
• CAMPFIELD LA, SMITH FJ: Leptin and other appetite suppressants. In: Pharmacotherapy of Obesity: Options and Alternatives, Hofbauer KG, Keller U, Boss O (Eds.), CRC Press, Boca Raton, FL (2004):321-344.
   Google Scholar
• WANG ZW, PAN WT, LEE Y, KAKUMA T, ZHOU YT, UNGER RH: The role of leptin resistance in the lipid abnormalities of aging. FASEB J. (2001) 15(1):108-114.
   PubMed Web of Science ®Google Scholar
• CHENG A, UETANI N, SIMONCIC PD et al.: Attenuation of leptin action and regulation of obesity by protein tyrosine phosphatase 1B. Dev. Cell (2002) 2(4):497-503.
   PubMed Web of Science ®Google Scholar
• KASZUBSKA W, FALLS HD, SCHAEFER VG et al.: Protein tyrosine phosphatase 1B negatively regulates leptin signaling in a hypothalamic cell line. Mol. Cell. Endocrinol. (2002) 195(1-2):109-118.
   PubMed Web of Science ®Google Scholar
• ZABOLOTNY JM, BENCE-HANULEC KK, STRICKER-KRONGRAD A et al.: PTP1B regulates leptin signal transduction in vivo. Dev. Cell (2002) 2(4):489-495.
   PubMed Web of Science ®Google Scholar
• SCHERER PE, WILLIAMS S, FOGLIANO M, BALDINI G, LODISH HF: A novel serum protein similar to C1q, produced exclusively in adipocytes. J. Biol. Chem. (1995) 270(45):26746-26749.
   PubMed Web of Science ®Google Scholar
• HU E, LIANG P, SPIEGELMAN BM: AdipoQ is a novel adipose-specific gene dysregulated in obesity. J. Biol. Chem. (1996) 271(18):10697-10703.
   PubMed Web of Science ®Google Scholar
• MAEDA K, OKUBO K, SHIMOMURA I, FUNAHASHI T, MATSUZAWA Y, MATSUBARA K: cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem. Biophys. Res. Commun. (1996) 221(2):286-289.
   PubMed Web of Science ®Google Scholar
• PAJVANI UB, DU X, COMBS TP et al.: Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications for metabolic regulation and bioactivity. J. Biol. Chem. (2003) 278(11):9073-9085.
   PubMed Web of Science ®Google Scholar
• HAVEL PJ: Update on adipocyte hormones: regulation of energy balance and carbohydrate/lipid metabolism. Diabetes (2004) 53(Suppl. 1):S143-S151.
   PubMed Web of Science ®Google Scholar
• BAJAJ M, SURAAMORNKUL S, PIPER P et al.: Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated Type 2 diabetic patients. J. Clin. Endocrinol. Metab. (2004) 89(1):200-206.
   PubMed Web of Science ®Google Scholar
• MIYAZAKI Y, MAHANKALI A, WAJCBERG E, BAJAJ M, MANDARINO LJ, DEFRONZO RA: Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in Type 2 diabetic patients. J. Clin. Endocrinol. Metab. (2004) 89(9):4312-4319.
   PubMed Web of Science ®Google Scholar
• BOUSKILA M, PAJVANI UB, SCHERER PE: Adiponectin: a relevant player in PPARgamma-agonist-mediated improvements in hepatic insulin sensitivity? Int. J. Obes. (2005) 29(Suppl. 1):S17-S23.
   Web of Science ®Google Scholar
• KADOWAKI T, YAMAUCHI T: Adiponectin and adiponectin receptors. Endocr. Rev. (2005) 26(3):439-451.
   PubMed Web of Science ®Google Scholar
• MAEDA N, SHIMOMURA I, KISHIDA K et al.: Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat. Med. (2002) 8(7):731-737.
   PubMed Web of Science ®Google Scholar
• MA K, CABRERO A, SAHA PK et al.: Increased beta -oxidation but no insulin resistance or glucose intolerance in mice lacking adiponectin. J. Biol. Chem. (2002) 277(38):34658-34661.
   PubMed Web of Science ®Google Scholar
• BERG AH, COMBS TP, DU X, BROWNLEE M, SCHERER PE: The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat. Med. (2001) 7(8):947-953.
   PubMed Web of Science ®Google Scholar
• COMBS TP, BERG AH, OBICI S, SCHERER PE, ROSSETTI L: Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J. Clin. Invest. (2001) 108(12):1875-1881.
   PubMed Web of Science ®Google Scholar
• FRUEBIS J, TSAO TS, JAVORSCHI S et al.: Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc. Natl. Acad. Sci. USA (2001) 98(4):2005-2010.
   PubMed Web of Science ®Google Scholar
• HEILBRONN LK, SMITH SR, RAVUSSIN E: The insulin-sensitizing role of the fat derived hormone adiponectin. Curr. Pharm. Des. (2003) 9(17):1411-1418.
   PubMed Web of Science ®Google Scholar
• YAMAUCHI T, KAMON J, ITO Y et al.: Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature (2003) 423(6941):762-769.
   PubMed Web of Science ®Google Scholar
• HUG C, WANG J, AHMAD NS, BOGAN JS, TSAO TS, LODISH HF: T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proc. Natl. Acad. Sci. USA (2004) 101(28):10308-10313.
   PubMed Web of Science ®Google Scholar
• YASRUEL Z, CIANFLONE K, SNIDERMAN AD, ROSENBLOOM M, WALSH M, RODRIGUEZ MA: Effect of acylation stimulating protein on the triacylglycerol synthetic pathway of human adipose tissue. Lipids (1991) 26(7):495-499.
   PubMed Web of Science ®Google Scholar
• FARAJ M, CIANFLONE K: Differential regulation of fatty acid trapping in mouse adipose tissue and muscle by ASP. Am. J. Physiol. Endocrinol. Metab. (2004) 287(1):E150-E159.
   PubMed Web of Science ®Google Scholar
• MURRAY I, SNIDERMAN AD, HAVEL PJ, CIANFLONE K: Acylation stimulating protein (ASP) deficiency alters postprandial and adipose tissue metabolism in male mice. J. Biol. Chem. (1999) 274(51):36219-36225.
   PubMed Web of Science ®Google Scholar
• MURRAY I, HAVEL PJ, SNIDERMAN AD, CIANFLONE K: Reduced body weight, adipose tissue, and leptin levels despite increased energy intake in female mice lacking acylation-stimulating protein. Endocrinology (2000) 141(3):1041-1049.
   PubMed Web of Science ®Google Scholar
• XIA Z, STANHOPE KL, DIGITALE E et al.: Acylation-stimulating protein (ASP)/complement C3adesArg deficiency results in increased energy expenditure in mice. J. Biol. Chem. (2004) 279(6):4051-4057.
   PubMed Web of Science ®Google Scholar
• CAIN SA, MONK PN: The orphan receptor C5L2 has high affinity binding sites for complement fragments C5a and C5a des-Arg(74). J. Biol. Chem. (2002) 277(9):7165-7169.
   PubMed Web of Science ®Google Scholar
• KALANT D, CAIN SA, MASLOWSKA M, SNIDERMAN AD, CIANFLONE K, MONK PN: The chemoattractant receptor-like protein C5L2 binds the C3a des-Arg77/acylation-stimulating protein. J. Biol. Chem. (2003) 278(13):11123-11129.
   PubMed Web of Science ®Google Scholar
• CIANFLONE K: Acylation stimulating protein and triacylglycerol synthesis: potential drug targets? Curr. Pharm. Des. (2003) 9(17):1397-1410.
   PubMed Web of Science ®Google Scholar
• MEIJSSEN S, VAN DIJK H, VERSEYDEN C, ERKELENS DW, CABEZAS MC: Delayed and exaggerated postprandial complement component 3 response in familial combined hyperlipidemia. Arterioscler. Thromb. Vasc. Biol. (2002) 22(5):811-816.
   PubMed Web of Science ®Google Scholar
• LAZAR MA: PPAR gamma, 10 years later. Biochimie (2005) 87(1):9-13.
   PubMed Web of Science ®Google Scholar
• YAMAUCHI T, WAKI H, KAMON J et al.: Inhibition of RXR and PPARgamma ameliorates diet-induced obesity and Type 2 diabetes. J. Clin. Invest. (2001) 108(7):1001-1013.
   PubMed Web of Science ®Google Scholar
• EVANS RM, BARISH GD, WANG YX: PPARs and the complex journey to obesity. Nat. Med. (2004) 10(4):355-361.
   PubMed Web of Science ®Google Scholar
• BERGER JP, PETRO AE, MACNAUL KL et al.: Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator. Mol. Endocrinol. (2003) 17(4):662-676.
   PubMed Web of Science ®Google Scholar
• ARGMANN CA, COCK TA, AUWERX J: Peroxisome proliferator-activated receptor gamma: the more the merrier? Eur. J. Clin. Invest. (2005) 35(2):82-92; discussion 80.
   PubMed Web of Science ®Google Scholar
• SMITH SR: Metabolic syndrome targets. Curr. Drug Targets CNS Neurol. Disord. (2004) 3(5):431-439.
   PubMedGoogle Scholar
• BERGER JP, AKIYAMA TE, MEINKE PT: PPARs: therapeutic targets for metabolic disease. Trends Pharmacol. Sci. (2005) 26(5):244-251.
   PubMed Web of Science ®Google Scholar
• KUBOTA N, TERAUCHI Y, MIKI H et al.: PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol. Cell (1999) 4(4):597-609.
   PubMed Web of Science ®Google Scholar
• MILES PD, BARAK Y, HE W, EVANS RM, OLEFSKY JM: Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency. J. Clin. Invest. (2000) 105(3):287-292.
   PubMed Web of Science ®Google Scholar
• YAMAUCHI T, KAMON J, WAKI H et al.: The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance. J. Biol. Chem. (2001) 276(44):41245-41254.
   PubMed Web of Science ®Google Scholar
• RIEUSSET J, TOURI F, MICHALIK L et al.: A new selective peroxisome proliferator-activated receptor gamma antagonist with antiobesity and antidiabetic activity. Mol. Endocrinol. (2002) 16(11):2628-2644.
   PubMed Web of Science ®Google Scholar
• CROWLEY VEF, VIDAL-PUIG AJ: Peripheral Targets for Antiobesity Drugs. In: Pharmacotherapy of Obesity: Options and Alternatives, Hofbauer KG, Keller U, Boss O (Eds.), CRC Press, Boca Raton, FL (2004):345-362.
   Google Scholar
• LUQUET S, LOPEZ-SORIANO J, HOLST D et al.: Roles of peroxisome proliferator-activated receptor delta (PPARdelta) in the control of fatty acid catabolism. A new target for the treatment of metabolic syndrome. Biochimie (2004) 86(11):833-837.
   PubMed Web of Science ®Google Scholar
• GRIMALDI PA: Regulatory role of peroxisome proliferator-activated receptor delta (PPAR delta) in muscle metabolism. A new target for metabolic syndrome treatment? Biochimie (2005) 87(1):5-8.
   PubMed Web of Science ®Google Scholar
• LUQUET S, LOPEZ-SORIANO J, HOLST D et al.: Peroxisome proliferator-activated receptor delta controls muscle development and oxidative capability. FASEB J. (2003) 17(15):2299-2301.
   PubMed Web of Science ®Google Scholar
• WANG YX, ZHANG CL, YU RT et al.: Regulation of muscle fiber type and running endurance by PPARdelta. PLoS Biol. (2004) 2(10):e294.
   PubMed Web of Science ®Google Scholar
• WANG YX, LEE CH, TIEP S et al.: Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. Cell (2003) 113(2):159-170.
   PubMed Web of Science ®Google Scholar
• TANAKA T, YAMAMOTO J, IWASAKI S et al.: Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc. Natl. Acad. Sci. USA (2003) 100(26):15924-5929.
   PubMed Web of Science ®Google Scholar
• MARCY TR, BRITTON ML, BLEVINS SM: Second-generation thiazolidinediones and hepatotoxicity. Ann. Pharmacother. (2004) 38(9):1419-1423.
   PubMed Web of Science ®Google Scholar
• MIYAZAKI M, KIM YC, GRAY-KELLER MP, ATTIE AD, NTAMBI JM: The biosynthesis of hepatic cholesterol esters and triglycerides is impaired in mice with a disruption of the gene for stearoyl-CoA desaturase 1. J. Biol. Chem. (2000) 275(39):30132-30138.
   PubMed Web of Science ®Google Scholar
• MIYAZAKI M, MAN WC, NTAMBI JM: Targeted disruption of stearoyl-CoA desaturase1 gene in mice causes atrophy of sebaceous and meibomian glands and depletion of wax esters in the eyelid. J. Nutr. (2001) 131(9):2260-2268.
   PubMed Web of Science ®Google Scholar
• JIANG G, LI Z, LIU F et al.: Prevention of obesity in mice by antisense oligonucleotide inhibitors of stearoyl-CoA desaturase-1. J. Clin. Invest. (2005) 115(4):1030-1038.
   PubMed Web of Science ®Google Scholar
• COHEN P, MIYAZAKI M, SOCCI ND et al.: Role for stearoyl-CoA desaturase-1 in leptin-mediated weight loss. Science (2002) 297(5579):240-243.
   PubMed Web of Science ®Google Scholar
• COHEN P, NTAMBI JM, FRIEDMAN JM: Stearoyl-CoA desaturase-1 and the metabolic syndrome. Curr. Drug Targets Immune Endocr. Metabol. Disord. (2003) 3(4):271-280.
   PubMedGoogle Scholar
• COHEN P, FRIEDMAN JM: Leptin and the control of metabolism: role for stearoyl-CoA desaturase-1 (SCD-1). J. Nutr. (2004) 134(9):2455S-2463S.
   Web of Science ®Google Scholar
• CHEN HC, FARESE RV, Jr.: Inhibition of triglyceride synthesis as a treatment strategy for obesity: lessons from DGAT1-deficient mice. Arterioscler. Thromb. Vasc. Biol. (2005) 25(3):482-486.
   PubMed Web of Science ®Google Scholar
• SMITH SJ, CASES S, JENSEN DR et al.: Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking Dgat. Nat. Genet. (2000) 25(1):87-90.
   PubMed Web of Science ®Google Scholar
• CHEN HC, SMITH SJ, LADHA Z et al.: Increased insulin and leptin sensitivity in mice lacking acyl CoA:diacylglycerol acyltransferase 1. J. Clin. Invest. (2002) 109(8):1049-1055.
   PubMed Web of Science ®Google Scholar
• CHEN HC, JENSEN DR, MYERS HM, ECKEL RH, FARESE RV, Jr.: Obesity resistance and enhanced glucose metabolism in mice transplanted with white adipose tissue lacking acyl CoA:diacylglycerol acyltransferase 1. J. Clin. Invest. (2003) 111(11):1715-1722.
   PubMed Web of Science ®Google Scholar
• GOLDSTEIN BJ: Protein-tyrosine phosphatase 1B (PTP1B): a novel therapeutic target for Type 2 diabetes mellitus, obesity and related states of insulin resistance. Curr. Drug Targets Immune Endocr. Metabol. Disord. (2001) 1(3):265-275.
   PubMedGoogle Scholar
• JOHNSON TO, ERMOLIEFF J, JIROUSEK MR: Protein tyrosine phosphatase 1B inhibitors for diabetes. Nat. Rev. Drug Discov. (2002) 1(9):696-709.
   PubMed Web of Science ®Google Scholar
• ELCHEBLY M, PAYETTE P, MICHALISZYN E et al.: Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science (1999) 283(5407):1544-1548.
   PubMed Web of Science ®Google Scholar
• KLAMAN LD, BOSS O, PERONI OD et al.: Increased energy expenditure, decreased adiposity, and tissue-specific insulin sensitivity in protein-tyrosine phosphatase 1B-deficient mice. Mol. Cell. Biol. (2000) 20(15):5479-5489.
   PubMed Web of Science ®Google Scholar
• RONDINONE CM, TREVILLYAN JM, CLAMPIT J et al.: Protein tyrosine phosphatase 1B reduction regulates adiposity and expression of genes involved in lipogenesis. Diabetes (2002) 51(8):2405-2411.
   PubMed Web of Science ®Google Scholar
• ZINKER BA, RONDINONE CM, TREVILLYAN JM et al.: PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice. Proc. Natl. Acad. Sci. USA (2002) 99(17):11357-11362.
   PubMed Web of Science ®Google Scholar
• GUM RJ, GAEDE LL, KOTERSKI SL et al.: Reduction of protein tyrosine phosphatase 1B increases insulin-dependent signaling in ob/ob mice. Diabetes (2003) 52(1):21-28.
   PubMed Web of Science ®Google Scholar
• WARING JF, CIURLIONIS R, CLAMPIT JE et al.: PTP1B antisense-treated mice show regulation of genes involved in lipogenesis in liver and fat. Mol. Cell. Endocrinol. (2003) 203(1-2):155-168.
   PubMed Web of Science ®Google Scholar
• SUZUKI T, HIROKI A, WATANABE T, YAMASHITA T, TAKEI I, UMEZAWA K: Potentiation of insulin-related signal transduction by a novel protein-tyrosine phosphatase inhibitor, Et-3,4-dephostatin, on cultured 3T3-L1 adipocytes. J. Biol. Chem. (2001) 276(29):27511-27518.
   PubMed Web of Science ®Google Scholar
• GUERTIN KR, SETTI L, QI L et al.: Identification of a novel class of orally active pyrimido[5,4-3][1,2,4]triazine-5,7-diamine-based hypoglycemic agents with protein tyrosine phosphatase inhibitory activity. Bioorg. Med. Chem. Lett. (2003) 13(17):2895-2898.
   PubMed Web of Science ®Google Scholar
• LIU G, SZCZEPANKIEWICZ BG, PEI Z et al.: Discovery and structure-activity relationship of oxalylarylaminobenzoic acids as inhibitors of protein tyrosine phosphatase 1B. J. Med. Chem. (2003) 46(11):2093-2103.
   PubMed Web of Science ®Google Scholar
• UMEZAWA K, KAWAKAMI M, WATANABE T: Molecular design and biological activities of protein-tyrosine phosphatase inhibitors. Pharmacol. Ther. (2003) 99(1):15-24.
   PubMed Web of Science ®Google Scholar
• CHEON HG, KIM SM, YANG SD, HA JD, CHOI JK: Discovery of a novel protein tyrosine phosphatase-1B inhibitor, KR61639: potential development as an antihyperglycemic agent. Eur. J. Pharmacol. (2004) 485(1-3):333-339.
   PubMed Web of Science ®Google Scholar
• DEAN D, ORLOWSKI L, COVERDALE S, WHITEHOUSE D, FAN C, BALKAN B: Chronic treatment with IDD-3, a Novel PTP1b inhibitor, results in sustained improvements in glucose homeostasis in ob/ob and db/db mice. Diabetes (2004) 53(Suppl. 2):516-P.
   Google Scholar
• FAN C, DEAN D, WHITEHOUSE DL, COVERDALE S, BALKAN B: The protein tyrosine phosphase-1B (PTP1B) inhibitor, IDD-3, acutely improves glucose homeostasis in ob/ob mice and insulin action in the euglycemic-hyperinsulinemic clamp in high fat fed rats. Diabetes (2004) 53(Suppl. 2):650-P.
   Google Scholar
• BALKAN B, BEELER S, FAN C, ORLOWSKI L, WHITEHOUSE D, DEAN DJ: Pharmacological inhibition of PTP1B prevents development of diet-induced obesity and insulin resistance. Diabetes (2004) 53(Suppl. 2):618-P.
   Google Scholar
• GRANNEMAN JG: Why do adipocytes make the beta 3 adrenergic receptor? Cell Signal. (1995) 7(1):9-15.
   PubMed Web of Science ®Google Scholar
• DENG C, PAOLONI-GIACOBINO A, KUEHNE F et al.: Respective degree of expression of beta 1-, beta 2- and beta 3-adrenoceptors in human brown and white adipose tissues. Br. J. Pharmacol. (1996) 118(4):929-934.
   PubMed Web of Science ®Google Scholar
• GRANNEMAN JG, LI P, ZHU Z, LU Y: Metabolic and cellular plasticity in white adipose tissue I: effects of beta3-adrenergic receptor activation. Am. J. Physiol. Endocrinol. Metab. (2005) 289(4):E608-E616.
   PubMed Web of Science ®Google Scholar
• LARSEN TM, TOUBRO S, VAN BAAK MA et al.: Effect of a 28-d treatment with L-796568, a novel beta(3)-adrenergic receptor agonist, on energy expenditure and body composition in obese men. Am. J. Clin. Nutr. (2002) 76(4):780-788.
   PubMed Web of Science ®Google Scholar
• HARPER M-E, DENT R, TESSON F, MCPHERSON R: Targeting Thermogenesis in the Development of Antiobesity Drugs. In: Pharmacotherapy of Obesity: Options and Alternatives, Hofbauer KG, Keller U, Boss O (Eds.), CRC Press, Boca Raton, FL (2004):363-383.
   Google Scholar
• COLLINS S, CAO W, ROBIDOUX J: Learning new tricks from old dogs: beta-adrenergic receptors teach new lessons on firing up adipose tissue metabolism. Mol. Endocrinol. (2004) 18(9):2123-2131.
   PubMed Web of Science ®Google Scholar
• MORTON NM, PATERSON JM, MASUZAKI H et al.: Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11 beta-hydroxysteroid dehydrogenase Type 1-deficient mice. Diabetes (2004) 53(4):931-938.
   PubMed Web of Science ®Google Scholar
• MASUZAKI H, PATERSON J, SHINYAMA H et al.: A transgenic model of visceral obesity and the metabolic syndrome. Science (2001) 294(5549):2166-2170.
   PubMed Web of Science ®Google Scholar
• KANNISTO K, PIETILAINEN KH, EHRENBORG E et al.: Overexpression of 11beta-hydroxysteroid dehydrogenase-1 in adipose tissue is associated with acquired obesity and features of insulin resistance: studies in young adult monozygotic twins. J. Clin. Endocrinol. Metab. (2004) 89(9):4414-4421.
   PubMed Web of Science ®Google Scholar
• MASUZAKI H, FLIER JS: Tissue-specific glucocorticoid reactivating enzyme, 11 beta-hydroxysteroid dehydrogenase Type 1 (11 beta-HSD1)-a promising drug target for the treatment of metabolic syndrome. Curr. Drug Targets Immune Endocr. Metabol. Disord. (2003) 3(4):255-262.
   PubMedGoogle Scholar
• SOUZA SC, DE VARGAS LM, YAMAMOTO MT et al.: Overexpression of perilipin A and B blocks the ability of tumor necrosis factor alpha to increase lipolysis in 3T3-L1 adipocytes. J. Biol. Chem. (1998) 273(38):24665-24669.
   PubMed Web of Science ®Google Scholar
• SOUZA SC, MULIRO KV, LISCUM L et al.: Modulation of hormone-sensitive lipase and protein kinase A-mediated lipolysis by perilipin A in an adenoviral reconstituted system. J. Biol. Chem. (2002) 277(10):8267-8272.
   PubMed Web of Science ®Google Scholar
• TANSEY JT, SZTALRYD C, GRUIA-GRAY J et al.: Perilipin ablation results in a lean mouse with aberrant adipocyte lipolysis, enhanced leptin production, and resistance to diet-induced obesity. Proc. Natl. Acad. Sci. USA (2001) 98(11):6494-6499.
   PubMed Web of Science ®Google Scholar
• SAHA PK, KOJIMA H, MARTINEZ-BOTAS J, SUNEHAG AL, CHAN L: Metabolic adaptations in the absence of perilipin: increased beta-oxidation and decreased hepatic glucose production associated with peripheral insulin resistance but normal glucose tolerance in perilipin-null mice. J. Biol. Chem. (2004) 279(34):35150-35158.
   PubMed Web of Science ®Google Scholar
• GROVER GJ, MELLSTROM K, YE L et al.: Selective thyroid hormone receptor-beta activation: a strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability. Proc. Natl. Acad. Sci. USA (2003) 100(17):10067-10072.
   PubMed Web of Science ®Google Scholar
• GROVER GJ, MELLSTROM K, MALM J: Development of the thyroid hormone receptor beta-subtype agonist KB-141: a strategy for body weight reduction and lipid lowering with minimal cardiac side effects. Cardiovasc. Drug Rev. (2005) 23(2):133-148.
   PubMed Web of Science ®Google Scholar
• LAZAR MA: A sweetheart deal for thyroid hormone. Endocrinology (2000) 141(9):3055-3056.
   PubMed Web of Science ®Google Scholar
• AREND WP: Interleukin 1 receptor antagonist. A new member of the interleukin 1 family. J. Clin. Invest. (1991) 88(5):1445-1451.
   PubMed Web of Science ®Google Scholar
• MATSUKI T, HORAI R, SUDO K, IWAKURA Y: IL-1 plays an important role in lipid metabolism by regulating insulin levels under physiological conditions. J. Exp. Med. (2003) 198(6):877-888.
   PubMed Web of Science ®Google Scholar
• SOMM E, HENRICHOT E, PERNIN A et al.: Decreased fat mass in interleukin-1 receptor antagonist deficient mice: impact on adipogenesis, food intake and energy expenditure. Diabetes (2005) 54:3503-3509.
   PubMed Web of Science ®Google Scholar
• HORAI R, SAIJO S, TANIOKA H et al.: Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J. Exp. Med. (2000) 191(2):313-320.
   PubMed Web of Science ®Google Scholar
• HIMMS-HAGEN J, MELNYK A, ZINGARETTI MC, CERESI E, BARBATELLI G, CINTI S: Multilocular fat cells in WAT of CL-316243-treated rats derive directly from white adipocytes. Am. J. Physiol. Cell. Physiol. (2000) 279(3):C670-C681.
   PubMed Web of Science ®Google Scholar
• GRANNEMAN JG, BURNAZI M, ZHU Z, SCHWAMB LA: White adipose tissue contributes to UCP1-independent thermogenesis. Am. J. Physiol. Endocrinol. Metab. (2003) 285(6):E1230-E1236.
   PubMed Web of Science ®Google Scholar
• HIMMS-HAGEN J: Exercise in a pill: feasibility of energy expenditure targets. Curr. Drug Targets CNS Neurol. Disord. (2004) 3(5):389-409.
   PubMedGoogle Scholar
• ROSSMEISL M, FLACHS P, BRAUNER P et al.: Role of energy charge and AMP-activated protein kinase in adipocytes in the control of body fat stores. Int. J. Obes. Relat. Metab. Disord. (2004) 28(Suppl. 4):S38-S44.
   PubMed Web of Science ®Google Scholar
• GUERRA C, KOZA RA, YAMASHITA H, WALSH K, KOZAK LP: Emergence of brown adipocytes in white fat in mice is under genetic control. Effects on body weight and adiposity. J. Clin. Invest. (1998) 102(2):412-420.
   PubMed Web of Science ®Google Scholar
• ROBIDOUX J, MARTIN TL, COLLINS S: Beta-adrenergic receptors and regulation of energy expenditure: a family affair. Ann. Rev. Pharmacol. Toxicol. (2004) 44:297-323.
   PubMed Web of Science ®Google Scholar
• WU Z, PUIGSERVER P, ANDERSSON U et al.: Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell (1999) 98(1):115-124.
   PubMed Web of Science ®Google Scholar
• SPIEGELMAN BM, PUIGSERVER P, WU Z: Regulation of adipogenesis and energy balance by PPARgamma and PGC-1. Int. J. Obes. Relat. Metab. Disord. (2000) 24(Suppl. 4):S8-S10.
   Google Scholar
• LIN J, WU H, TARR PT et al.: Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres. Nature (2002) 418(6899):797-801.
   PubMed Web of Science ®Google Scholar
• KAMEI Y, OHIZUMI H, FUJITANI Y et al.: PPARgamma coactivator 1beta/ERR ligand 1 is an ERR protein ligand, whose expression induces a high-energy expenditure and antagonizes obesity. Proc. Natl. Acad. Sci. USA (2003) 100(21):12378-12383.
   PubMed Web of Science ®Google Scholar
• MEIRHAEGHE A, CROWLEY V, LENAGHAN C et al.: Characterization of the human, mouse and rat PGC1 beta (peroxisome-proliferator-activated receptor-gamma co-activator 1 beta) gene in vitro and in vivo. Biochem J. (2003) 373(Pt 1):155-165.
   PubMed Web of Science ®Google Scholar
• ST-PIERRE J, LIN J, KRAUSS S et al.: Bioenergetic analysis of peroxisome proliferator-activated receptor gamma coactivators 1alpha and 1beta (PGC-1alpha and PGC-1beta) in muscle cells. J. Biol. Chem. (2003) 278(29):26597-25603.
   PubMed Web of Science ®Google Scholar
• LIN J, HANDSCHIN C, SPIEGELMAN BM: Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab. (2005) 1(6):361-370.
   PubMed Web of Science ®Google Scholar
• YOON JC, PUIGSERVER P, CHEN G et al.: Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature (2001) 413(6852):131-138.
   PubMed Web of Science ®Google Scholar
• KNUTTI D, KRESSLER D, KRALLI A: Regulation of the transcriptional coactivator PGC-1 via MAPK-sensitive interaction with a repressor. Proc. Natl. Acad. Sci. USA (2001) 98(17):9713-9718.
   PubMed Web of Science ®Google Scholar
• FAN M, RHEE J, ST-PIERRE J et al.: Suppression of mitochondrial respiration through recruitment of p160 myb binding protein to PGC-1alpha: modulation by p38 MAPK. Genes Dev. (2004) 18(3):278-289.
   PubMed Web of Science ®Google Scholar
• SCHREIBER SN, KNUTTI D, BROGLI K, UHLMANN T, KRALLI A: The transcriptional coactivator PGC-1 regulates the expression and activity of the orphan nuclear receptor estrogen-related receptor alpha (ERRalpha). J. Biol. Chem. (2003) 278(11):9013-9018.
   PubMed Web of Science ®Google Scholar
• MOOTHA VK, HANDSCHIN C, ARLOW D et al.: Erralpha and Gabpa/b specify PGC-1alpha-dependent oxidative phosphorylation gene expression that is altered in diabetic muscle. Proc. Natl. Acad. Sci. USA (2004) 101(17):6570-6575.
   PubMed Web of Science ®Google Scholar
• SCHREIBER SN, EMTER R, HOCK MB et al.: The estrogen-related receptor alpha (ERRalpha) functions in PPARgamma coactivator 1alpha (PGC-1alpha)-induced mitochondrial biogenesis. Proc. Natl. Acad. Sci. USA (2004) 101(17):6472-6477.
   PubMed Web of Science ®Google Scholar
• WILLY PJ, MURRAY IR, QIAN J et al.: Regulation of PPARgamma coactivator 1alpha (PGC-1alpha) signaling by an estrogen-related receptor alpha (ERRalpha) ligand. Proc. Natl. Acad. Sci. USA (2004) 101(24):8912-8917.
   PubMed Web of Science ®Google Scholar
• KALLEN J, SCHLAEPPI JM, BITSCH F et al.: Evidence for ligand-independent transcriptional activation of the human estrogen-related receptor alpha (ERRalpha): crystal structure of ERRalpha ligand binding domain in complex with peroxisome proliferator-activated receptor coactivator-1alpha. J. Biol. Chem. (2004) 279(47):49330-49337.
   PubMed Web of Science ®Google Scholar
• SCHULMAN IG, HEYMAN RA: The flip side: Identifying small molecule regulators of nuclear receptors. Chem. Biol. (2004) 11(5):639-646.
   PubMedGoogle Scholar
• LANGIN D, LUCAS S, LAFONTAN M: Millennium fat-cell lipolysis reveals unsuspected novel tracks. Horm. Metab. Res. (2000) 32(11-12):443-452.
   PubMed Web of Science ®Google Scholar
• LI P, ZHU Z, LU Y, GRANNEMAN JG: Metabolic and cellular plasticity in white adipose tissue II: role of peroxisome proliferator-activated receptor-alpha. Am. J. Physiol. Endocrinol. Metab. (2005) 289(4):E617-E626.
   PubMed Web of Science ®Google Scholar
• XUE B, COULTER A, RIM JS, KOZA RA, KOZAK LP: Transcriptional synergy and the regulation of Ucp1 during brown adipocyte induction in white fat depots. Mol. Cell. Biol. (2005) 25(18):8311-8322.
   PubMed Web of Science ®Google Scholar
• BODKIN NL, PILL J, MEYER K, HANSEN BC: The effects of K-111, a new insulin-sensitizer, on metabolic syndrome in obese prediabetic rhesus monkeys. Horm. Metab. Res. (2003) 35(10):617-624.
   PubMed Web of Science ®Google Scholar
• SCHAFER SA, HANSEN BC, VOLKL A, FAHIMI HD, PILL J: Biochemical and morphological effects of K-111, a peroxisome proliferator-activated receptor (PPAR)alpha activator, in non-human primates. Biochem. Pharmacol. (2004) 68(2):239-251.
   PubMed Web of Science ®Google Scholar
• RABEN DM, BALDASSARE JJ: A new lipase in regulating lipid mobilization: hormone-sensitive lipase is not alone. Trends Endocrinol. Metab. (2005) 16(2):35-36.
   PubMed Web of Science ®Google Scholar
• ZECHNER R, STRAUSS JG, HAEMMERLE G, LASS A, ZIMMERMANN R: Lipolysis: pathway under construction. Curr. Opin. Lipidol. (2005) 16(3):333-340.
   PubMed Web of Science ®Google Scholar
• MCFEE RB, CARACCIO TR, MCGUIGAN MA, REYNOLDS SA, BELLANGER P: Dying to be thin: a dinitrophenol related fatality. Vet. Hum. Toxicol. (2004) 46(5):251-254.
   PubMedGoogle Scholar